Titre du document / Document title

Finasteride increases anagen hair in men with androgenetic alopecia

Auteur(s) / Author(s)

VAN NESTE D. ⁽¹⁾ ; FUH V. ⁽¹⁾ ; SANCHEZ-PEDRENO P. ⁽²⁾ ; LOPEZ-BRAN E. ⁽³⁾ ; WOLFF H. ⁽⁴⁾ ; WHITING D. ⁽⁵⁾ ; ROBERTS J. ⁽⁶⁾ ; KOPERA D. ⁽⁷⁾ ; STENE J.-J. ⁽⁸⁾ ; CALVIERI S. ⁽⁹⁾ ; TOSTI A. ⁽¹⁰⁾ ; PRENS E. ⁽¹¹⁾ ; GUARRERA M. ⁽¹²⁾ ; KANOJIA P. ⁽¹³⁾ ; HE W. ⁽¹⁴⁾ ; KAUFMAN K. D. ⁽¹⁵⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Skin Study Center-Skinterface, Tournai, BELGIQUE
⁽²⁾ Department of Clinical Research, Merck Sharpe & Dohme, Hoddesdon, ROYAUME-UNI
⁽³⁾ Hospital Virgen de la Arrixaca, Murcia, ESPAGNE
⁽⁴⁾ Hospital Clinico San Carlos, Madrid, ESPAGNE
⁽⁵⁾ Department of Dermatology, Ludwig-Maximilians-University, Munich, ALLEMAGNE
⁽⁶⁾ Dallas Associated Dermatologists, Dallas, TX, ETATS-UNIS
⁽⁷⁾ Northwest Cutaneous Research Specialists, Portland, OR, ETATS-UNIS
⁽⁸⁾ Department of Dermatology, University of Graz, Graz, AUTRICHE
⁽⁹⁾ H.A.I.R. Technology®-Skinterface, Brussels, BELGIQUE
⁽¹⁰⁾ Università degli Studi di Roma, Rome, ITALIE
⁽¹¹⁾ Università di Bologna, Bologna, ITALIE
⁽¹²⁾ Ziekenhuis Walcheren, Vlissingen, PAYS-BAS
⁽¹³⁾ Università di Genova, Genova, ITALIE
⁽¹⁴⁾ Department of Clinical Research, Merck Research Laboratories, 126 E. Lincoln Avenue, RY 33-500, Rahway, NJ 07065-0900, ETATS-UNIS
⁽¹⁵⁾ Department of Biostatistics, Merck Research Laboratories, 126 E. Lincoln Avenue, RY 33-500, Rahway, NJ, ETATS-UNIS

Résumé / Abstract

Background The growth of scalp hair is a cyclical process of successive phases of growth (anagen) and rest (telogen). In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i.e. increased hair density). Objectives The current study used a phototrichogram methodology to assess the effect of finasteride on the phases of the hair growth cycle. Patients/Methods Two hundred and twelve men, age 18-40 years, with androgenetic alopecia were randomized to receive finasteride 1 mg daily or placebo for 48 weeks. At baseline and at 24 and 48 weeks, macrophotographs were taken to measure total and anagen hair count in a 1-cm² target area of the scalp. Results At baseline, mean total and anagen hair counts in the finasteride group were 200 and 124 hairs, respectively (% anagen = 62%) and the anagen to telogen ratio was 1.74 (geometric mean). In the placebo group, the respective values were 196 and 119 hairs (% anagen = 60%) and 1.57. At week 48, the finasteride group had a net improvement (mean ± SE) compared with placebo in total and anagen hair counts of 17.3 ± 2.5 hairs (8.3% ± 1.4%) and 27.0 ± 2.9 hairs (26% ± 3.1%), respectively (P < 0.001). Furthermore, treatment with finasteride resulted in a net improvement in the anagen to telogen ratio of 47% (P < 0.001). In this study, treatment with finasteride 1 mg day^-1 for 48 weeks increased both total and anagen hair counts, and improved the anagen to telogen ratio. Conclusions These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. These data support that finasteride treatment results in favourable effects on hair quality that contribute to the visible improvements in hair growth observed in treated patients.

Revue / Journal Title

British journal of dermatology   ISSN 0007-0963   CODEN BJDEAZ 

Source / Source

2000, vol. 143, n^o4, pp. 804-810 (19 ref.)

Langue / Language

Anglais

Editeur / Publisher

Blackwell, Oxford, ROYAUME-UNI  (1951) (Revue)

Mots-clés anglais / English Keywords

Finasteride ; Biological activity ; Hair (head) ; Androgenetic alopecia ; Male ; Human ; Antihormone ; Azasteroid ; Antiandrogen ; Skin disease ;

Mots-clés français / French Keywords

Finastéride ; Activité biologique ; Cheveu ; Alopécie androgénétique ; Mâle ; Homme ; Antihormone ; Azastéroïde ; Antiandrogène ; Peau pathologie ;

Mots-clés espagnols / Spanish Keywords

Finasterida ; Actividad biológica ; Cabello ; Alopecia androgenética ; Macho ; Hombre ; Antihormona ; Azasteroide ; Antiandrógeno ; Piel patología ;

Localisation / Location

INIST-CNRS, Cote INIST : 1043, 35400009257024.0170